Aligos Therapeutics, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
ALGS
Aligos Therapeutics, Inc. Common Stock
$7.65 +36.85%
VS HALOHalozyme Therapeutics, Inc.
$102.62 -0.48%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| ALGS | HALO | |
|---|---|---|
| Market Cap | $47.77 million | $11.65 billion |
| Revenue (TTM) | — | $1.66 billion |
| Net Income (TTM) | — | $413.60 million |
HALO leads on 1 of 1 size & scale factors.
Valuation
| ALGS | HALO | |
|---|---|---|
| P/E Ratio | — | 30.01 |
| Price / Book | — | 81.14 |
| Price / Sales | — | 7.00 |
ALGS and HALO split the valuation factors evenly.
Profitability
| ALGS | HALO | |
|---|---|---|
| Net Margin | — | 24.86% |
| Return on Equity | — | 288.13% |
ALGS and HALO split the profitability factors evenly.
Risk & Sentiment
| ALGS | HALO | |
|---|---|---|
| Short Interest | 36.27% | 9.79% |
HALO leads on 1 of 1 risk & sentiment factors.
Dig deeper: ALGS overview, ALGS financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.